Copyright: ©Author(s) 2026.
World J Virol. Mar 25, 2026; 15(1): 116055
Published online Mar 25, 2026. doi: 10.5501/wjv.v15.i1.116055
Published online Mar 25, 2026. doi: 10.5501/wjv.v15.i1.116055
Figure 2 From elite neutralisers, B-cells producing broad neutralising antibodies are isolated, and antibody genes are extracted and cloned into expression vectors for production.
Applications include: (1) Passive immunisation via bnAb infusions for immediate viral control; (2) Germline targeting vaccines designed to activate bnAb precursor B-cells; and (3) Gene therapy delivering bnAb genes for long-term endogenous production.
- Citation: Varatharajan S, Krishnasai S, Girish C. Human immunodeficiency virus vaccines: Advances, challenges and future perspectives. World J Virol 2026; 15(1): 116055
- URL: https://www.wjgnet.com/2220-3249/full/v15/i1/116055.htm
- DOI: https://dx.doi.org/10.5501/wjv.v15.i1.116055